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Abstract: Anaplastic lymphoma kinase (ALK) gene rearrangements have been identified in lung
cancer at 3–7% frequency, thus representing an important subset of genetic lesions that drive
oncogenesis in this disease. Despite the availability of multiple FDA-approved small molecule
inhibitors targeting ALK fusion proteins, drug resistance to ALK kinase inhibitors is a common
problem in clinic. Thus, there is an unmet need to deepen the current understanding of genomic
characteristics of ALK rearrangements and to develop novel therapeutic strategies that can overcome
ALK inhibitor resistance. In this review, we present the genomic landscape of ALK fusions in the
context of co-occurring mutations with other cancer-related genes, pointing to the central role of
genetic epistasis (gene-gene interactions) in ALK-driven advanced-stage lung cancer. We discuss
the possibility of targeting druggable domains within ALK fusion partners in addition to available
strategies inhibiting the ALK kinase domain directly. Finally, we examine the potential of targeting
ALK fusion-specific neoantigens in combination with other treatments, a strategy that could open a
new avenue for the improved treatment of ALK positive lung cancer patients.
Keywords: anaplastic lymphoma kinase; ALK; dimerization inhibition; neoantigens; CAR-T;
immunotherapy
1. Introduction
The human Anaplastic lymphoma kinase (ALK) gene is located on chromosome 2p23.2 and
encodes an enzymatic protein, also known as ALK tyrosine kinase receptor or CD246 (cluster of
differentiation 246). The ALK receptor tyrosine kinase belongs to the insulin receptor superfamily.
This protein comprises an extracellular domain, a hydrophobic stretch corresponding to a single pass
transmembrane region, and an intracellular kinase domain [1] (Figure 1A). The expression levels
of ALK mRNA and protein are diminished after birth and maintain relatively low levels in most
tissues (Figure 1B, adopted from [2]), except showing high expression in the brain suggesting an
important role in brain development [3]. This finding is supported by the behavioral phenotype
apparent in ALK gene knockout mice [4]. In mammals, ligands binding to the ALK protein are not
well-defined, but pleiotropin (PTN) [5], Midkine (MK) [6] and FAM150A/B [7,8] are considered as
potential interaction partners. Upon ligand binding, ALK receptors are dimerized, resulting in kinase
domain phosphorylation and the activation of multiple downstream signaling pathways such as
JAK/STAT3, PI3K/AKT, RAS/MAPK and PLC-γ pathways (Figure 1C).
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Figure 1. Genomic location and expression of ALK in physiological condition. (A) The human ALK 
gene is located on Chr2 p23.2–23.1 and expresses an RNA transcript of approximately 6267 kb 
encompassing 29 exons. The encoded protein contains 1602 amino acids with extracellular domains 
of two meprin, A-5 protein, multiple receptor protein-tyrosine phosphatase mu (MAM) regions and 
a low-density lipoprotein receptor domain class A (LDLa), a transmembrane domain (TM) and 
intracellular kinase domain (TKD). (B) The distribution of normal ALK protein expression in a 
variety of tissues/organs. adopted from the human protein atlas [2]. (C) ALK is a receptor tyrosine 
kinase. It is activated by ligand-binding and subsequent phosphorylation, transduces signaling 
through well-characterized JAK/STAT3, PI3K/AKT, RAS/MAPK, and PLC-gamma pathways. Three 
known ligands are: pleiotrophin (PTN), Midkin (MK) and FAM150A/B. 
The ALK gene has been found to be rearranged, mutated, or amplified in a series of tumors 
including anaplastic large cell lymphomas (ALCL), neuroblastoma, and non-small cell lung cancer 
(NSCLC) [9]. Chromosomal rearrangements are the most common alterations in this gene and 
result in creation of genetic fusions such as EML4 (chromosome 2)-ALK (chromosome 2) [10], 
RANBP2 (chromosome 2)-ALK, ATIC (chromosome 2)-ALK, TFG (chromosome 3)-ALK, NPM1 
Figure 1. Genomic location and expression of ALK in physiological condition. (A) The human
ALK gene is located on Chr2 p23.2–23.1 and expresses an RNA transcript of approximately 6267 kb
encompassing 29 exons. The encoded protein contains 1602 amino acids with extracellular domains of
two meprin, A-5 protein, multiple receptor protein-tyrosine phosphatase mu (MAM) regions and
a low-density lipoprotein receptor domain class A (LDLa), a transmembrane domain (TM) and
intracellular kinase domain (TKD). (B) The distribution of normal ALK protein expression in a variety
of tissues/organs. adopted from the human protein atlas [2]. (C) ALK is a receptor tyrosine kinase.
It is activated by ligand-binding and subsequent phosphorylation, transduces signaling through
well-characterized JAK/STAT3, PI3K/AKT, RAS/MAPK, and PLC-gamma pathways. Three known
ligands are: pleiotrophin (PTN), Midkin (MK) and FAM150A/B.
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The ALK gene has been found to be rearranged, mutated, or amplified in a series of tumors
including anaplastic large cell lymphomas (ALCL), neuroblastoma, and non-small cell lung cancer
(NSCLC) [9]. Chromosomal rearrangements are the most common alterations in this gene and
result in creation of genetic fusions such as EML4 (chromosome 2)-ALK (chromosome 2) [10],
RANBP2 (chromosome 2)-ALK, ATIC (chromosome 2)-ALK, TFG (chromosome 3)-ALK, NPM1
(chromosome 5)-ALK, SQSTM1 (chromosome 5)-ALK, KIF5B (chromosome 10)-ALK, CLTC
(chromosome 17)-ALK, TPM4 (chromosome 19)-ALK, and MSN (chromosome X)-ALK (Table 1). The
incidence of ALK rearrangements is 3–7% in NSCLC [11,12], and novel rare ALK fusion partner genes
(e.g., GCC2, LMO7, and PHACTR1) continue to be discovered [13]. Clinically and pathologically,
the ALK-rearranged subtype of NSCLC forms a distinct entity among lung adenocarcinomas,
usually characterized by young onset, non- or light-smoking history, poor-differentiation with
acinar-predominant structure and with mucin/signet-ring cell pattern on histological analysis [14–16].
Characterization of the molecular subtypes of NSCLC revealed that ALK-rearranged NSCLC tends
to be mutually exclusive with oncogenic EGFR and KRAS mutations [14]. Furthermore, unique
microRNA expression signatures were found to distinguish ALK-rearranged NSCLC from EGFR and
KRAS mutated NSCLC [17].
The general features of ALK fusions that activate ALK function across the various fusion partners
are: (1) the regulatory regions (e.g., active promoter) of the partner gene may initiate constitutive
transcription of ALK fusion RNA resulting in overexpression of the ALK fusion protein; (2) unique
domains in the partner proteins can influence the subcellular localization of ALK fusion proteins,
which can reside in the nucleus, in the cytoplasm, and on cellular membranes; and (3) dimerization of
ALK fusion proteins and thus activation of the ALK kinase domain through phosphorylation occurs
in a ligand-independent fashion and is mediated by functional domains within the fusion partner
(e.g., coiled-coil domains) or oligomerization at subcellular locations [18,19]. Since the discovery of
the EML4-ALK fusion oncogene in lung cancer in 2007 [20,21], targeted therapies aiming to inhibit
the constitutively activate ALK kinase domain have been the main focus for cancer therapy. The first
small molecule ALK inhibitor, crizotinib, was approved by FDA in 2011. Second generation ALK
inhibitors including ceritinib, alectinib, and brigatinib target both therapy-naïve and crizotinib-resistant
ALK positive lung cancers with acquired ALK mutations, and next generation ALK inhibitors are in
various stages of clinical trials [22]. The major challenge is that ALK+ NSCLCs initially respond to
treatment but inevitably develop resistance to each ALK inhibitor, resulting in clinical relapse. The
mechanisms of ALK inhibitor resistance are not completely understood, but ALK gene amplification,
different mutations in the ALK kinase domain and bypass signaling pathways contribute to resistance
(see recent review [22]) (Figure 2). Ongoing research in academia and the pharmaceutical industry
aims to identify treatment options to overcome as well as delay or prevent resistance development,
which is beyond the focus of this article. Here, we update the genomic landscape of ALK fusion-driven
NSCLC, propose non-canonical ideas to manipulate the partner proteins in ALK fusions, and propose
the design of novel immune-epitopes for potential ALK fusion targeted immunotherapy.
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Figure 2. Resistance mechanisms in ALK fusion-positive lung cancer. A subset of lung cancer is driven
by clonal ALK-rearranged genetic alterations. Top panel (A) depicts general categories of ALK tyrosine
kinase inhibitor (TKI) resistance mechanisms. The oncogene-addicted ALK+ lung cancer cells initially
respond to ALK tyrosine kinase inhibitors treatment (e.g., crizotinib treatment) followed by relapse
due to acquired resistance, via ALK gene amplification, and/or ALK mutations, and/or bypass track
activation or other unknown mechanisms. Middle panel (B) delineates the molecular mechanisms of
each ALK TKI resistance phenotypes in addition to ALK rearrangement genetic alteration. Acquired
mutations in ALK kinase domain are a well-known underlying molecular mechanism of ALK TKI
resistance. Resistance mutations are listed here, highlighted with different colors: pink, crizotinib
resistance; blue, alectinib resistance; and purple, ceritinib resistance. The ALK G1202R mutation is
resistant to crizotinib, alectinib, and ceritinib. Rare compound mutations such as C1156Y and L1198F
are resistant to loratinib, but sensitive to crizotinib, details see reference [19]. Bottom panel (C) lists
treatment options for different types of ALK TKI resistance. Many FDA-approved ALK inhibitors
(e.g., crizotinib, alectinib, and ceritinib) could be used to target acquired TKI resistance; other small
molecules (e.g., EGFR inhibitors, MEK inhibitors, MET inhibitors, CDK4/CDK6 inhibitors or IGF-1R
inhibitors) could be used to target bypass tracts with coexisting genetic alterations. Conventional
chemotherapy, HSP90 inhibitor, immunotherapy and cancer vaccines are other options to treat the
remaining subset of inhibitor-resistant ALK positive lung cancers. For ALK gene amplification resistant
cases, chimeric antigen receptor-T cells therapy or microRNA-based therapy may be investigational
treatment options.
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2. Genomic Characteristics of ALK Fusion-Driven NSCLC
ALK fusions in NSCLC are found in the majority of young, non- or light-smoking patients, and
were originally reported to be mutually exclusive with KRAS or EGFR mutations [14,23]. With the
application of next generation sequencing in the diagnosis of cancer patients, NSCLC cases harboring
ALK genetic rearrangement concurrent with other somatic mutations have been detected. In contrast
to previous reports, recent cases present co-occurrence of ALK fusion and EGFR mutations [24,25] as
co-driver genetic alterations and indicate epistatic effects on malignant transformation or progression.
Consistent with the notion of co-occurring genetic events in ALK+ lung cancer, Tan et al. reported [26]
that 13 additional different somatic gene alterations coexist with ALK-fusion in 71 lung cancer cases
analyzed. Recurrence of these gene mutations from high frequency to low frequency are TP53,
CDKN2A/B, SETD2, MYC, MCL1, RICTOR, EGFR, MSH6, MYST3, CCND1, and CDK4. The vast
majority of concurrent gene alterations are cell cycle related genes (TP53, CDKN2A/B, MYC, CCND1,
and CDK4), followed by epigenetic modifying gene mutations (SETD2 and MYST3) and survival
and proliferative pathway genes (MCL1, RICTOR, and EGFR). Recent large genomic data analysis
revealed 57 somatic co-mutations in NSCLC patients (n = 129) harboring EML4-ALK fusion protein;
the top 10 co-mutated genes were: TP53, ARID1A, ATPX, NF1, NOTCH1, ROS1, ARID1B, CSF1R,
ALK, APC, FLT3, NPM1, and SMAD4 [13]. Of note, the aforementioned data were obtained from
targeted DNA sequencing. Thus, it is anticipated that an additional order of magnitude of genetic
aberrations co-occurring with ALK fusions in lung cancer could be detected with whole genome or
whole exome sequencing analysis. These previously unappreciated co-occurring genetic alterations
as well as the activation of IGF-1R-IRS-1 pathway [27] may cooperate with the oncogenic function of
ALK in promoting lung cancer progression and therapy resistance in both the targeted therapy-naïve
and the acquired resistance setting.
The genomic landscape of ALK rearrangements with other genetic alterations, though
characterized in small cohorts to date, provides a rationale for potential combinatorial treatment
of ALK inhibitors with other known or novel small molecule inhibitors (i.e., ALK/EGFR co-alterations,
ALK/KRAS co-alterations or IGF-1R-IRS-1 pathway activation) [24,27,28]. It is also worth noting that
epigenetic regulatory genes might be a promising therapeutic target in ALK fusion positive tumors.
This is evident in recent studies [29], which demonstrated that specific lysine residues (e.g., 1451, 1455
and 1610) in EML4-ALK proteins were methylated by a lysine methyltransferase, SET and MYND
domain-containing 2 (SMYD2). Preventing methylation of these lysine residues via either knockdown
of SMYD2 or treatment with a SMYD2 inhibitor significantly attenuated the phosphorylation levels
of EML4-ALK and inhibited downstream AKT activation. More strikingly, combination treatment
with a SMYD2 inhibitor and an ALK inhibitor additively suppressed the growth of NSCLC cells,
compared with single-agent treatment [29]. Therefore, the complexity of ALK fusion protein-mediated
signaling, activated not only by constitutive phosphorylation within the kinase domain, but also by
methylation of the ALK protein, together with epistatic effects of co-occurring mutations, could be of
central importance for the development of potent next generation ALK inhibitors and the design of
combinational therapeutic approaches.
In addition to co-alterations in coding genes in ALK+ lung cancer, studies have shown
a unique signature of non-coding microRNA expression associated with ALK rearranged lung
cancer [17,30,31]. Overexpression of miR-1343-3p and reduced expression of miR-671-3p, miR-103a-3p,
let-7e, and miR-342-3p were especially distinctive in the ALK-rearranged lung cancer compared
with EGFR-mutated and KRAS-mutated lung cancer [17]. Further, the ALK transcript represents
a target of post-transcriptional, negative regulation by microRNAs. Using the miRWalk 2.0 algorithm
(http://zmf.umm.uni-heidelberg.de/apps/zmf/mirwalk2/generetsys-self.html), 98 microRNAs were
predicted to potentially bind to the ALK (Refseq ID: NM_004304) 3′ untranslated region (3′ UTR),
which is present in the ALK fusion gene. If these microRNAs were experimentally verified, the small
non-coding RNAs could be used to universally silence expression of wild type ALK or ALK fusion
transcripts [31].
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3. ALK Fusion Partner Proteins as Potential Therapeutic Targets
Rearrangements of ALK with a variety of different cellular proteins have been identified (Table 1).
Among the most abundant are fusions of the ALK gene with portions of the gene encoding the
echinoderm microtubule-associated protein-like 4 (EML4) in lung cancer (Figure 3A) [20,32–36].
In addition, genetic fusions of ALK with genes such as KIF5B, TFG, DCTN1, SQSTM1, TPR, CRIM1,
STRN, HIP1, PTPN3, KLC1, CLTC, and FBXO36 have been discovered (Figure 3B) [21,22,26,33,37–44].
Besides differential capacity of ALK fusion variants regarding tumorigenesis in xenograft mouse
models [45] as well as differential propensity to acquire additional mutations resulting in ALK TKI
resistance (with more resistance-associated mutations in EML4-ALK variant 3 than non-variant 3) [46],
the composition and characteristics of the ALK fusion partner can influence patient response to
treatment with ALK inhibitors. This is exemplified in multiple reports indicating a better response of
EML4-ALK variant 1 (E13;A20)- and variant 2 (E20;A20)-harboring patients compared to variant 3
(E6a/b;A20)-positive cases to ALK inhibitors, such as crizotinib, alectinib, or ceritinib [47–50]. Of note,
Heuckmann et al. revealed that treatment response to ALK inhibitors correlates with protein stability
of different EML4-ALK fusion proteins, with variant 3 (E6a/b;A20) as the shortest ALK fusion and
with greater protein stability compared to other variants [47]. Analyzing the role of different protein
domains present in EML4 regarding their effect on protein stability, the authors showed that deletion
of the WD40 repeats but not the HELP domain resulted in a markedly increased stability of EML4-ALK
variant 2 (E20;A20) fusions, mimicking the behavior of EML4-ALK variant 3 (E6a/b;A20) [47]. This
indicates a significant negative role of the WD40 repeats on stability of the ALK fusion protein. Other
studies have noted that the longer KIF5B-ALK fusion was markedly more sensitive than the shorter
fusion, NPM-ALK, to ALK inhibitor treatment [47]. ALK fusion variants can also change protein
structures (e.g., TAPE domain in the EML4 protein) of the partner proteins and require heat shock
protein 90 to stabilize the resulting misfolded proteins. For example, EML4-ALK variant 1 and 2 contain
a partial TAPE domain and become the substrate of HSP90; therefore, these ALK fusion proteins are
sensitive to HSP90 inhibition, unlike EML4-ALK 3a/b and 5 [51]. This is further strengthened by
synthetic lethality for combinatorial HSP90 inhibition upon treatment with the ALK inhibitor crizotinib,
opening the possibility to overcome de novo treatment resistance of ALK fusion proteins that show an
increased stability under crizotinib treatment alone [47].Cancers 2017, 9, 164 7 of 18 
 
 
Figure 3. Schematic structural composition of ALK fusion proteins. (A) EML4-ALK fusion proteins. 
The breakpoint in the ALK gene is at exon 20; the breakpoint in EML4 is at different exons (e.g., 2, 6, 
13, 14, 15, 18, and 20), resulting in variable EML4-ALK fusion proteins. In detail, variant 1 (E13;A20) 
and variant 2 (E20;A20) contain exons 1 to 13 and 1 to 20 of EML4, respectively, fused to exon 20 of 
ALK. Thus, the portion of EML4 includes its C-terminal coiled coil domain, HELP domain and parts 
of the WD repeat domain of EML4. Variant 3a/b EML4-ALK fusion proteins (E6a/b;A20) consist of 
exons 1 to 6 of EML4, with exon 6b being 188bp downstream of exon 6a, fused to exon 20 of ALK. 
Variant 4 (E14;E20) contain exons 1 to 14 of EML4, insertion of four amino acids of unknown origin, 
and fusion to exon 20 of ALK N-terminally lacking 49bp. Variant 5 EML4-ALK fusion proteins 
(E2a/b;A20) present a fusion of exon 2 of EML4 to exon 20 of ALK (E2a;A20) or to 117bp upstream of 
exon 20 of ALK (E2b;A20). Variant 6 (E13b;A20) contains exons 1 to 13 of EML4 fused to exon 20 of 
ALK with an insertion of 19 amino acids derived from upstream intron 19. Variant 7 (E14;A20) 
represents a genetic fusion of EML4 at exon 14 with ALK at exon 20, the latter lacking the first four 
amino acids. Variant “4” (E15;A20) is characterized as a fusion product of EML4 at exon 15 and ALK 
at exon 20. Variant “5” (E18;E20) consists of exon 1 to 18 of EML4 fused to exon 20 of ALK. (B) Other 
X-ALK fusion proteins. X represents any fusion partner including, amongst others, KIF5B-ALK 
(K24;A20 and K15;A20), TFG-ALK (T3;A20), DCTN1-ALK (D26;A20), SQSTM1-ALK (S5;A20), 
TPR-ALK (T15;A20), STRN-ALK (S3;A20), HIP1-ALK (H21;A20), and CLTC-ALK (C31;A20). For (A) 
and (B), protein domains are indicated by color and include: coiled coil (CC, light orange), HELP 
(dark orange), WD repeats (dark green), ALK kinase domain (blue), kinesin (ocher), PB1 (dark 
grey), CAP-Gly (light green), dynactin (dark red), zinc finger (ZZ, light violet), striatin (dark violet), 
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Figure 3. Schematic structural composition of ALK fusion proteins. (A) EML4-ALK fusion proteins.
The breakpoint in the ALK gene is at exon 20; the breakpoint in EML4 is at different exons (e.g., 2, 6,
13, 14, 15, 18, and 20), resulting in variable EML4-ALK fusion proteins. In detail, variant 1 (E13;A20)
and variant 2 (E20;A20) contain exons 1 to 13 and 1 to 20 of EML4, respectively, fused to exon 20 of
ALK. Thus, the portion of EML4 includes its C-terminal coiled coil domain, HELP domain and parts
of the WD repeat domain of EML4. Variant 3a/b EML4-ALK fusion proteins (E6a/b;A20) consist of
exons 1 to 6 of EML4, with exon 6b being 188bp downstream of exon 6a, fused to exon 20 of ALK.
Variant 4 (E14;E20) contain exons 1 to 14 of EML4, insertion of four amino acids of unknown origin, and
fusion to exon 20 of ALK N-terminally lacking 49bp. Variant 5 EML4-ALK fusion proteins (E2a/b;A20)
present a fusion of exon 2 of EML4 to exon 20 of ALK (E2a;A20) or to 117bp upstream of exon 20 of
ALK (E2b;A20). Variant 6 (E13b;A20) contains exons 1 to 13 of EML4 fused to exon 20 of ALK with
an insertion of 19 amino acids derived fr m upstream intron 19. Variant 7 (E14;A20) represents a
genetic fusion of EML4 at exon 14 with ALK at exon 20, the latter la king the first f ur amino acids.
Variant “4” (E15;A20) is characterized as a fusion product of EML4 at exon 15 and ALK at exon 20.
Variant “5” (E18;E20) consists of xon 1 to 18 of EML4 fused to exon 20 of ALK. (B) Other X-ALK
fusion proteins. X represents any fusion partner including, amongst others, KIF5B-ALK (K24;A20 and
K15;A20), TFG-ALK (T3;A20), DCTN1-ALK (D26; 20), SQSTM1-ALK (S5;A20), TPR-ALK (T15; 20),
STRN-ALK (S3;A20), HIP1-ALK (H21;A20), and CLTC-ALK (C31;A20). For (A) and (B), protein
domains are indicated by color and include: coiled coil (CC, light orange), HELP (dark orange), WD
repeats (dark green), ALK kinase domain (blue), kinesin (ocher), PB1 (dark grey), CAP-Gly (light
green), dynactin (dark red), zinc finger (ZZ, light violet), striatin (dark violet), ANTH (light yellow),
clathrin-binding (light red), clathrin propeller (olive green), clathrin link (light grey), and clathrin
(petrol) domains. Protein domains are derived from Pfam database [52]. See Table 1 for a list of ALK
fusion partners and encoded protein domains.
Targeting proteins interacting with EML4-ALK might improve treatment response to ALK
inhibitors such as crizotinib or alectinib. In a recent study by Zhang et al., an EML4-ALK interactome
was defined and additional proteins that mediate an increased response to ALK inhibitor upon
knockdown have been identified [53]. The latter set of genes comprises scaffolding proteins, such
as FRS2 (Fibroblast growth factor receptor substrate 2) and CC2D1A (Coiled-Coil and C2 Domain
Containing 1A) [53]. These scaffolding proteins may participate in ALK-fusion protein-mediated
downstream pathway activation; therefore, combinatorial inhibition of the interaction of EML4-ALK
and the respective signaling protein(s) by competitive binding peptides or inhibitors as well as
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by downregulation/degradation of scaffolding proteins might improve therapeutic response of
EML4-ALK driven NSCLC patients to ALK inhibitor therapy.
Besides an important role of functional domains contained in the fusion partner for treatment
response to ALK inhibitors, their composition is equally important to ALK-mediated oncogenesis.
As outlined in Table 1, the majority of ALK fusion partners contain coiled-coil domains—central
mediators of the oligomerization of proteins and often found in cytoskeletal proteins and associated
motor proteins [54]. The fusion of proteins harboring a coiled-coil-domain with the kinase-encoding
portion of ALK most likely allows dimerization and constitutive activation of ALK, as previously
noted [21]. This was confirmed by Soda et al. when studying the functional relevance of EML4 protein
domains present in the EML4-ALK variant 1 fusion protein (E13;A20) regarding the transforming ability
of the ALK fusion protein [20]. EML4-ALK variant 1 expression constructs encoding the full length
fusion protein or fusion proteins lacking the basic domain (∆31–140 including deletion of coiled-coil
domain at residues 17–51), the HELP domain (∆220–296), or the WD40 repeats (∆305–475) were
transfected into 3T3 cells and their ability to form tumors was assessed in vivo [20]. While deletion of
WD40 repeats did not impair tumor formation, deletion of the EML4 HELP domain resulted in reduced
tumor outgrowth [20]. Most importantly, deletion of the basic domain, generating an EML4 protein
lacking its N-terminal coiled-coil domain, completely abolished tumor formation in vivo—again
confirming the central role of protein dimerization via the coiled-coil domain of the ALK fusion partner
in constitutive ALK signaling and ALK-mediated oncogenesis [20]. Further, the reduction of tumor
outgrowth upon deletion of the HELP domain may point to an additive role of the EML4 fusion partner
in driving oncogenesis. Recent evidence published by our laboratory indicated that EML4-ALK fusion
proteins engage Ras-MAPK signaling via the EML4 HELP domain [55]. In particular, deletion of the
HELP domain contained within EML4 in the EML4-ALK variant 1 (E13;A20) fusion protein impaired
the intracellular localization of the fusion protein and diminished GTP loading of Ras, resulting in
reduced Ras-MAPK signaling [55]. Of note, cases positive for EML4-ALK fusion proteins that contain
the EML4 HELP domain might show an improved response to rational combinational therapy targeting
MAPK signaling in addition to ALK directly, as outlined in our recent publication [55].
In addition to EML4, gene ontology (GO) enrichment analysis confirms an over-representation
of microtubule or microtubule-associated proteins among ALK fusion partners (data not shown).
Oligomerization and activation of ALK due to distinct intracellular localization at microtubules (EML4,
KIF5B, TFG, DCTN1, PTPN3, and KLC1) or cellular membranes (SQSTM1, TPR, CRIM1, STRN,
HIP1, and CLTC) is likely to be of central relevance for ALK-mediated oncogenesis and presents a
new therapeutic target for the treatment of ALK fusion driven cancers. Pharmacologic compounds
that impair the formation of ALK signaling complexes need to be developed and tested to evaluate
this hypothesis directly. Amongst others, microtubule-destabilizing agents are already approved
as single or combination therapy in solid and hematologic cancers [56], but their discrete benefit
in ALK fusion positive lung cancer has not been studied. Similarly, the inhibition of kinesin and
dynactin domain-mediated association of ALK fusion proteins with microtubules might be beneficial
for KIF5B-DCTN1-or KLC1-ALK harboring cases, with inhibitors already being available but not
tested in ALK+ NSCLC [57–60]. Most importantly, novel coiled coil mimetics or other helical peptides
and peptidomimetic inhibitors that hamper oligomerization of ALK fusion associated signaling
proteins offer another promising approach [61,62]. As shown for Bcl-Abl proteins, targeting protein
dimerization by interfering with the coiled-coil domain significantly impacts fusion protein-driven
oncogenesis [63]. In the context of the relevance of protein dimerization for ALK-mediated signaling
and oncogenesis of ALK fusion protein, the use and therapeutic benefit of similar drugs as single-agent
or combinational therapy in ALK fusion positive NSCLC warrants evaluation.
4. Immunotherapy for ALK+ Lung Cancer
Immunotherapy aims to establish or enhance an effective immune response against tumor cells.
This could be accomplished via different strategies, including tumor vaccination, adoptive transfer of
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immune cells, and modification of the immune system to boost an established immune response [64].
The conventional immunotherapy such as vaccination against tumor-associated antigens exhibited
limited anti-tumor effect in the past [65]. With the discovery of inhibitory pathways in immune
cells, so called checkpoint molecules, and the development of antibody-based blockades against
these checkpoint molecules such as cytotoxic T lymphocyte-associated protein 4 (CTLA-4) and
programmed cell death protein (PD-1)/PD1 ligand 1(PD-L1), cancer immunotherapy is entering
a new era [66]. Recently, immune checkpoint inhibitors (ICI) against PD-1 have been tested in NSCLC,
and an objective response rate of up to 20% has been observed in selected patients with high PD-L1
expression [67–69]. In general, patients with squamous NSCLC respond to ICI better than patients with
non-squamous-NSCLC, and, amongst the latter, a better response for lung adenocarcinoma patients
with a heavy smoking history than those with light- or non-smoking record has been reported [70].
The differences between “smoker” and “non-smoker” NSCLC patient cohorts that are causally linked
to their ICI response may include the following: (1) genomically, smokers usually harbor higher
mutational burden and thus have a higher number of expressed neoantigens than non-smokers; and
(2) the tumor microenvironment (TME) in smokers is characterized by an increased frequency of
active, tumor-infiltrating CD8+ T cells as well as increased levels of anti-tumor cytokines such as IFN-γ
and granzyme, while the TME in non-smokers shows elevated immunosuppressive features such
as a high number of FOXP3+ regulatory T cells, the accumulation of M2-like macrophages and less
activated effector CD8+ T cells [71]. ALK rearranged lung adenocarcinoma is characterized by patients
with non- or light-smoking history and mutational burden in this subtype of NSCLC is incompletely
characterized; intuitively, it is inferred that the number of non-synonymous mutations is lower than
median number of 192 in lung cancers more generally [72]. In current clinical trials of lung cancer
immune checkpoint blockade treatment, patients with ALK fusion and EGFR mutation have shown
minimal responses [67,69]. Experimental evidence showed that lung cancers with ALK fusion harbor
an immune-suppressive TME and a T-cell exhausted state [73]. Therefore, converting the TME in
ALK+ NSCLC to such extent that an effective immune response against the tumor will become possible
remains an important challenge.
How might the immune-unresponsive TME be converted to a responsive TME? Neoantigen-based
cancer vaccination could activate T cells and promote tumor-associated infiltrating effector
lymphocytes into the TME [74].
Tumor neoantigens are the products of all genetic alterations accumulated in cancer genome
during tumorigenesis. The neoantigens are superior to other tumor-associated antigens due to:
(1) neoantigens are presented only in tumor cells; (2) neoantigens are not subject to central tolerance
in the thymus; and (3) neoantigens produce strong immunogenicity, with persistent cytotoxic T cell
activation. These antigens can arise not only from missense mutations but also fusion transcripts [75]
or any altered open reading frame that encodes novel stretches of amino acids that are not encoded in
the normal genome.
As we mentioned in the introduction section, ALK expression is normally restricted to a subset of
cells in the nervous system. Its pathological expression in lung cancer and most other malignancies is
due to chromosomal translocations that lead to the formation of an ALK-derived oncogenic fusion
proteins, which are overexpressed and constitutively activated in cancer cells. The high level of
ALK fusion protein expression in cancer cells and its direct role in tumorigenesis, in line with the
fact that normal ALK is expressed at low levels in the immune privileged nervous system, makes
it an ideal tumor-specific target for immunotherapy in ALK fusion-positive NSCLC. The presence
of anti-NPM-ALK antibodies in ALCL patients has been reported and indicates that patients are
able to respond to ALK-derived neoantigens [76]. From the ALK kinase domain, two HLA-A2.1
restricted CD8+ T-cell epitopes, p280–289 (SLAMLDLLHV) and p375–389 (GVLLWEIFSL) were
identified and confirmed to be immunogenic in HLA-matched ALCL and neuroblastoma cell lines [77].
In principle, these peptides could be used for vaccinations against ALK fusion antigens in cancer
patients including NSCLC; however, more experimental tests on humanized mouse or clinical trials
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need to be performed. Chiarle et al. [78] have shown that DNA vaccination with plasmids encoding
portions of the cytoplasmic domain of ALK, which has been translocated in different fusion proteins
that are necessary for the growth of ALCL, protects mice from local and systemic lymphoma growth.
The protection is potent and durable by eliciting an ALK-specific interferon-gamma response and
CD8+ T cell-mediated cytotoxicity. A combination of chemotherapy and vaccination significantly
enhanced the survival of mice challenged with ALK+ lymphomas [78]. These findings indicate that
ALK represents a compelling tumor antigen for vaccination-based therapies of ALCL and possibly
other ALK+ human tumors. The efficacy of DNA-based vaccination was also observed in lung cancer
xenograft models with EML4-ALK as well as in a TFG-ALK transgenic lung cancer mouse model [73].
In animals with high tumor burden, the anti-tumor effect of an ALK vaccine is diminished. This
may correlate with an exhausted phenotype of T cells and PD-L1 expression. Thus, the combination
of an ALK vaccine and ALK inhibitors, as expected, increased the anti-tumor efficacy [73] due to an
increase of neoantigens and possible tumor microenvironment changes (e.g., more tumor-infiltrating
lymphocytes). PD-L1 expression is increased in ALK+ lung cancer cells through downstream pathway
signaling, in particular ERK and AKT activation but not JAK/STAT3/5 signaling [79]. Given a higher
objective response rate of anti-PD-1 and anti-CTLA-4 in PD-L1 positive lung cancer, it is reasonable
to consider adding anti-PD-1 and/or anti-PD-L1 antibodies to the treatment of ALK+ lung cancer,
particularly at the time of resistance to ALK inhibitor monotherapy.
When we analyzed the ALK fusion with various partners listed in Figure 3 and Table 1, we noted
that some gene rearrangements include extra sequence from introns or insertions (e.g., EML4-ALK
variant 3a/b, 4, and 5b); such DNA alterations create new protein peptides that might be immunogenic.
In addition, there are more than 20 different mutations in ALK fusion proteins [80]; whether these
mutated peptides could be developed into therapeutic vaccines remains to be investigated.
Therapy with autologous T cells that have been genetically-engineered to express chimeric antigen
receptors (CAR) or T cell receptors (TCR) provides a feasible and emerging treatment for certain cancer
patients [81]. Since amplification of ALK (native) can result in ALK TKI resistance, an antibody against
extracellular domain of ALK receptor is alterative potential approach to treatment [82,83]. Moreover,
a chimeric antigen receptor of T cells targeting the ALK protein could provide a novel adoptive
T-cell-targeted therapy. For example, T cells expressing a CAR incorporating a scFv of the ALK48 mAb
linked to a 4-1BB-CD3ζ signaling domain elicited ALK-expressing tumor lysis and produced IFN-γ
upon antigen stimulation, but limited anti-tumor efficacy was observed in xenograft models of human
neuroblastoma [84].
Taken together, ALK rearranged lung cancer appears to exhibit an immune-suppressive or anergic
tumor microenvironment. Neoantigens produced from ALK fusion proteins or other co-occurring gene
mutations may stimulate the host immune system and re-reactivate effector T cells. Neoantigen-based
vaccines could provide an alternative therapeutic option to treat refractory ALK+ cancers such as
lung cancer.
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Table 1. Characterization of ALK fusion partners in NSCLC.
Protein Name 1
Reported
ALK Fusion Uniprot ID Molecular Function
2 Subcellular Localization 3 Protein Domains 4
Echinoderm
microtubule-associated
protein-like 4 (EML4)
E2a/b;A20 [36]
Q9HC35
Microtubule binding
and assembly
Cytoplasm > cytoskeleton
Coiled coil [aa17–51]
HELP [aa225–297]
WD40 repeats [aa229–347, 499–537, 583–620,
711–749, 824–863]
E6a/b;A20 [32]
E13;A20 [20]
E13b;A20 [33]
E14;A20 [33,36]
E15;A20 [34]
E18;A20 [35]
E20;A20 [20]
Kinesin-1 heavy chain
(KIF5B)
K24;A20
K15;A20
[33]
[43] P33176
Microtubule-associated
motor protein Cytoplasm > cytoskeleton
Kinesin [aa14–325]
Coiled coil [aa330–364, 418–543, 594–684, 691–711,
716–757, 768–802, 825–912]
TRK-fused gene
(TFG) T3;A20 [21] Q92734
Dynamic interaction of
endoplasmic reticulum and
microtubules
Endoplasmic reticulum (ER) PB1 [aa10–93]Coiled coil [aa102–122]
Dynactin subunit 1
(DCTN1) D26;A20 [37] Q14203
Dynein-mediated retrograde
transport of vesicles and
organelles along microtubules
Cytoplasm > cytoskeleton >
microtubule
CAP-Gly [aa29–94]
Coiled coil [aa217–352, 360–383,388–540,
952–1043, 1185–1205]
Dynactin [aa527–805]
Sequestosome-1
(SQSTM1) S5;A20 [37] Q13501
Autophagy receptor, endosome
organization
Cytoplasm > late endosome,
autolysosome/-phagosome
PB1 [aa21–102]
Zinc finger [aa122–165]
UBA [aa379–440]
Nucleoprotein TPR T15;A20 [38] P12270
Scaffolding element in nuclear
pore complex,
nucleocytoplasmic transport
Nucleus > Nuclear pore
complex
Coiled coil [aa29–49, 61–172, 219–281, 293–366,
427–513, 543–570, 576–596, 665–752, 760–801,
827–868, 887–914, 934–982, 997–1071, 1096–1116,
1149–1169, 1221–1238, 1269–1303, 1311–1345,
1354–1416, 1469–1552, 1564–1598, 1603–1630]
TPR/MLP1/MLP2 [aa1038–1165]
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Protein Name 1
Reported
ALK Fusion Uniprot ID Molecular Function
2 Subcellular Localization 3 Protein Domains 4
Cysteine-rich motor
neuron 1 protein
(CRIM1)
n/a [26] Q9NZV1
Tissue development,
interaction with transforming
growth factor beta
family proteins
Cell membrane
Single pass type I transmembrane [aa1–34]
IGFBP [aa37–90]
VWC [aa336–390, 403–456, 608–662, 679–734,
753–808, 819–873]
Antistatin [aa469–498, 505–532, 539–564, 567–592]
Striatin (STRN) S3;A20 [39] O43815
Calmodulin-binding protein
involved in scaffolding
and signaling
Cytoplasm,
Cell membrane
Striatin [aa48–177]
Coiled coil [aa67–115]
WD40 repeats [aa453–491, 506–544, 559–597,
696–734, 738–779]
Huntingtin-interacting
protein 1 (HIP1) H21;A20 [40] O00291
Involved in clathrin-mediated
endocytosis and trafficking
Cytoplasm, Endomembrane
system, nucleus
ANTH [aa39–308]
Coiled coil [aa377–397, 409–488, 496–555, 584–611,
978–1007]
Clathrin binding [aa482–580]
I/LWEQ [aa862–1010]
Tyrosine-protein
phosphatase
non-receptor type 3
(PTPN3)
Chimeric
fusion [44] P26045
Tyrosine phosphatase,
interaction with cytoskeleton
Cell membrane, cytoplasm >
cytoskeleton
FERM [aa33–97, 113–222, 226–316]
PDZ [aa510–595]
Y phosphatase [aa670–900]
Kinesin light chain 1
(KLC1) K9;A20 [41] Q07866
Microtubule-associated
motor protein Cytoplasm > cytoskeleton n/a
Clathrin heavy
chain 1 (CLTC) C31;A20 [22] Q00610
Intracellular trafficking and
endocytosis
Cell membrane, cytoplasm >
cytoskeleton
Clathrin propeller repeat [aa19–56, 148–187,
198–234, 253–288, 296–330]
Clathrin (H) link [aa331–354, 356–421]
Clathrin [aa537–679, 686–827,835–971, 979–1123,
1128–1268, 1274–1419, 1424–1565]
F-box only protein 36
(FBXO36) n/a [42] Q8NEA4
Substrate recognition in E3
ubiquitin ligase complex n/a
F-box [aa92–139]
Coiled coil [aa166–186]
1,2,3 Information retrieved from UniProt database (http://www.uniprot.org), accessed on 9 April 2017 [85]; 4 Information retrieved from Pfam database (http://pfam.xfam.org), accessed
on 9 April 2017 [52]. Protein domains are underlined and include coiled-coiled domain, hydrophobic EMAP-like protein (HELP) motif, WD40 repeats, kinesin domain, PB1 domain,
cytoskeleton-associated protein (CAP)-Gly domain, dynactin motif, ZZ-type zinc finger domain, ubiquitin associated (UBA) domain, TPR/myosin-like protein (MLP) 1/2 motif, single
pass type I transmembrane domain, insulin-like growth factor binding protein (IGFBP) motif, von Willebrand factor type C (VWC) domain, antistatin domain, striatin domain, ANTH
domain, clathrin binding domain, I/LWEQ domain, FERM domain (F, 4.1 protein; E, ezrin, R, radixin; M, moesin), PDZ domain, Y phosphatase domain, clathrin propeller repeat, clathrin
(H) link, clathrin domain, and F-box domain.
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5. Conclusions and Future Perspectives
ALK gene rearrangements are present in 3–7% of NSCLC. The fusion proteins encoded by ALK
fusion genes are constitutively activate kinases and drive various oncogenic functions [13,45]. Since
the identification of first EML4-ALK aberrations in lung cancer in 2007 [20], ALK-specific inhibitors
(e.g., crizotinib) have been developed. Lung cancer patients harboring ALK fusion initially respond to
TKIs, leading to tumor regression, but tumors inevitably relapse due to multiple resistance mechanisms
such as acquired mutations in ALK, ALK amplification, and the aforementioned concurrent genetic
alterations within the cancer genome. Interestingly, the composition of ALK fusion proteins determines
sensitivity to ALK inhibitor treatment and patient outcome during therapy. Fusion partners of ALK
play a central role in mediating dimerization and constitutive ALK signaling, both by facilitating
distinct intracellular localization(s) as well as protein oligomerization. Further, ALK fusion partners
themselves might engage additive signaling pathways that support ALK-mediated oncogenesis.
While there is a strong focus on the development of next generation inhibitors targeting emerging
resistance mutations, we propose a non-canonical strategy to fight ALK fusion positive NSCLC. In brief,
we propose: (1) to target specific domains in partners of ALK fusion proteins to inactivate ALK kinase
function; (2) to trigger a specific immune response against ALK-fusion proteins (e.g., via peptide
vaccines); and (3) to develop combinatorial treatment approaches that can target coexisting genetic
alterations in ALK positive NSCLC. Although these hypotheses need to be tested through multiple
avenues before moving to the clinic, we are optimistic that these ideas may have clinical implications
by expanding the therapeutic options for lung cancer patients.
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